This strategy was effective to kill Bcl-2-dependent cell models, including primary CLL cells18, DLBCL cell models19, small cell lung cancer (SCLC) cells20, and multiple myeloma and follicular lymphoma21. The gene discussed is BCL2; the disease is plasma cell myeloma.